Vertex Pharmaceuticals (VRTX) Stock Price Target Reduced at Jefferies

NEW YORK (TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) price target was cut to $108 from $116 at Jefferies.

However, the firm has maintained its "buy" rating on the stock.

The Boston, MA-based company discovers, develops, manufactures and commercializes small molecule therapeutics, with a focus on cystic fibrosis.

Back by Popular Demand…“Confessions of a Street Addict” Get a FREE signed copy of Jim Cramer’s national best-seller when you gain access to his multi-million dollar charitable trust portfolio! Click here to see Jim’s holdings and get your FREE gift.

The new price target comes ahead of the company's 2016 first quarter earnings, which are scheduled to be released on April 27.

Regarding the company's drug Orkambi, "it is unclear if the company will have enough data points on...